Production of New Adenovector Constructs with Fiber-Shaft Modifications

$1,113,792Z01FY2007AINIH

Niaid Extramural Activities

Investigators

Linked publications & trials

Paper 20523899 Paper 19349466 Paper 19017266 Paper 18775675 Paper 18761012 Paper 18586952 Paper 18552283 Paper 18203260 Paper 18083827 Paper 17822404 Paper 17724033 Paper 17715365 Paper 17562855 Paper 17481635 Paper 17379721 Paper 17305424 Paper 17267054 Paper 17266530 Paper 17242151 Paper 17170306 Paper 17022100 Paper 16920791 Paper 16881408 Paper 16835460 Paper 16801557 Paper 16778769 Paper 16674839 Paper 16621068 Paper 16600400 Paper 16530971 Paper 16400169 Paper 16339723 Paper 16339717 Paper 16330111 Paper 16324218 Paper 16287846 Paper 16266757 Paper 16246004 Paper 16244709 Paper 16188255 Paper 16185873 Paper 16182390 Paper 16159678 Paper 16149193 Paper 15922242 Paper 15917510 Paper 15860593 Paper 15785854 Paper 15729590 Paper 15701805 Paper 15684324 Paper 15535864 Paper 15317876 Paper 15280394 Paper 15279956 Paper 15170259 Paper 15123738 Paper 15104593 Paper 15075278 Paper 15003493 Paper 15003492 Paper 15003490 Paper 15003488 Paper 14973196 Paper 14747151 Paper 14711585 Paper 14509838 Paper 12860390 Paper 12446678

Abstract

This project is designed to prepare a GMP quality investigational HIV vaccine and complete the preclinical and laboratory studies needed for clinical studies of a multicomponent HIV-1 adenoviral vector vaccine. The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to HIV-1. Subjects receive adenovector vaccine either as a single agent or as a boost after priming with plasmid DNA vaccines. The Vaccine Research Center (VRC), NIAID is developing a novel prime-boost HIV vaccine strategy directed at the most globally prevalent HIV subtypes (clades). VRC's HIV prime-boost candidate is designed to elicit immune responses to HIV sequences from stains most commonlyHIV infections around the world. The VRC is developing modified adenovectors that should be less susceptible to the potential inhibition effects of high prevalance of Ad5 neutralising antibodies.

View original record on NIH RePORTER →